An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 21, 2026 - P1 | N=42 | Completed | Sponsor: Ono Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Oct 2025 | Trial primary completion date: Sep 2026 ➔ Oct 2025
Trial completion • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|